| Literature DB >> 26479761 |
Martin Häusler1, Ayse Aksoy2, Michael Alber3, Sakir Altunbasak4, Aydan Angay5, Oana Tarta Arsene6, Dana Craiu6, Hans Hartmann7, Semra Hiz-Kurul8, Takashi Ichiyama9, Catrinel Iliescu6, Bosanka Jocic-Jakubi10, Rudolf Korinthenberg11, Gülsen Köse12, Marissa B Lukban13, Mehpare Ozkan2, Iliyana Patcheva14, Jens Teichler15, Mihaela Vintan16, Ahmet Yaramis17, Coskun Yarar18, Uluc Yis8, Deniz Yuksel2, Banu Anlar19.
Abstract
Subacute sclerosing panencephalitis (SSPE) is a chronic infection of the central nervous system caused by the measles virus (MV). Its prevalence remains high in resource poor countries and is likely to increase in the Northern Europe as vaccination rates decrease. Clinical knowledge of this devastating condition, however, is limited. We therefore conducted this multinational survey summarizing experience obtained from more than 500 patients treated by 24 physicians in seven countries. SSPE should be considered in all patients presenting with otherwise unexplained acquired neurological symptoms. In most patients, the diagnosis will be established by the combination of typical clinical symptoms (characteristic repetitive myoclonic jerks), a strong intrathecal synthesis of antibodies to MV and typical electroencephalogram findings (Radermecker complexes). Whereas the therapeutic use of different antiviral (amantadine, ribavirin) and immunomodulatory drugs (isoprinosine, interferons) and of immunoglobulins has been reported repeatedly, optimum application regimen of these drugs has not been established. This is partly due to the absence of common diagnostic and clinical standards focusing on neurological and psychosocial aspects. Carbamazepine, levetiracetam, and clobazam are the drugs most frequently used to control myoclonic jerks. We have established a consensus on essential laboratory and clinical parameters that should facilitate collaborative studies. Those are urgently needed to improve outcome. Georg Thieme Verlag KG Stuttgart · New York.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26479761 DOI: 10.1055/s-0035-1564618
Source DB: PubMed Journal: Neuropediatrics ISSN: 0174-304X Impact factor: 1.947